H.C. Wainwright reiterates Incyte rating on JAK inhibitor data
UKPulse Money Desk
H.C. Wainwright has reiterated its rating on Incyte stock, citing JAK inhibitor data. The announcement was made on 3 August 2026.
- H.C. Wainwright reiterated its rating on Incyte stock.
- The reiteration follows JAK inhibitor data.
- The news was reported on 3 August 2026.
H.C. Wainwright has reiterated its rating on Incyte Corporation stock, according to a report on 3 August 2026. The decision follows data related to the company's JAK inhibitor programme.
The brokerage's stance was reaffirmed without any change to its previous rating, though specific details of the rating or price target were not disclosed.